Skip to content

Genomics and COVID-19 Vaccine Adverse Events

Vaccine Adverse Reaction

Vaccines routinely used are extremely safe; however, severe adverse events to vaccines do occur. As vaccination against COVID-19 has begun, adverse events to the vaccine, particularly Guillain-Barré syndrome (GBS), vaccine-induced immune thrombotic thrombocytopenia (VITT)/thrombosis with thrombocytopenia syndrome (TTS), and myocarditis/pericarditis, after COVID-19 vaccination have been reported worldwide.

Study hypothesis: there are genetic factors that contribute to increased risks of particular COVID-19 vaccine-induced adverse events.

The objective of the study is to determine if there are specific genetic factors strongly associated with each of the COVID-19 vaccine-induced adverse events (i.e., GBS, VITT/TTS, and myocarditis/pericarditis).

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    5 and up

Participation Criteria

Inclusion Criteria:

* Case: Any patient who received COVID-19 vaccines and developed GBS, VITT/TTS, or myocarditis/pericarditis after vaccination
* Control: Any participant who received COVID-19 vaccines and does not experience GBS, VITT/TTS, or myocarditis/pericarditis.

Exclusion Criteria:

* Individuals who have not received a COVID-19 vaccine
* Individuals who are unable to provide informed consent

Study Location

British Columbia Children's Hospital Research Institute
British Columbia Children's Hospital Research Institute
Vancouver, British Columbia
Canada

Contact Study Team

Primary Contact

Bruce Carleton, PharmD

Study Sponsored By
University of British Columbia
Participants Required
More Information
Study ID: NCT05212792